Intergalactic Therapeutics, a startup focused on non-viral gene therapy, reports positive preclinical results for its lead program, IG-002, addressing all forms of ABCA4-related retinopathies.
Affibody and Inmagene Biopharmaceuticals report that the US FDA has cleared the interleukin-17 (IL-17) blocker, izokibep, to proceed to phase 2 clinical development in non-infectious intermediate, posterior, and pan-uveitis.